FIELD: medicine, pharmaceutics.
SUBSTANCE: pro-apoptotic solid dispersion contains a compound, e.g. ABT-263 taken in a substantially non-crystalline form to inhibit Bcl-2 proteins and dispersed in a solid binding substance containing (a) a pharmaceutically acceptable water-soluble polymer carrier and (b) a pharmaceutically acceptable surfactant. A method for preparing this solid dispersion involving dissolving the compound, polymer carrier and surfactant in an acceptable dissolution medium and removing the dissolution medium to form the solid binding substance containing the polymer carrier and surfactant and possessing a compound dispersed therein in the substantially non-crystalline form.
EFFECT: solid dispersion is orally applicable in the individual in need thereof for treating a disease characterised by the overexpression of one or more anti-apoptotic Bcl-2 proteins, eg a malignant new growth.
22 cl, 6 ex, 2 tbl, 3 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| STABILISED LIPID PREPARATIVE FORM OF APOPTOSIS PROMOTER | 2010 |
|
RU2530642C2 |
| ABT-263 CAPSULE | 2010 |
|
RU2550956C2 |
| PHARMACEUTICAL DOSAGE FORM FOR ORAL ADMINISTRATION OF BCL-2 FAMILY INHIBITOR | 2010 |
|
RU2711359C2 |
| PHARMACEUTICAL DOSED FORM FOR PERORAL INTRODUCTION OF BCL-2 FAMILY INHIBITOR | 2010 |
|
RU2568599C2 |
| ABT-263 CRYSTALLINE FORMS AND SOLVATES FOR TREATMENT OF BCL-2 PROTEIN RELATED DISEASES | 2010 |
|
RU2551376C2 |
| SOLID DISPERSIONS, CONTAINING KINASE INHIBITORS | 2011 |
|
RU2566716C2 |
| PHARMACEUTICAL COMBINATIONS FOR TREATING A MALIGNANT TUMOR | 2017 |
|
RU2726367C2 |
| CRYSTALLINE BROMODOMAIN INHIBITORS | 2014 |
|
RU2675268C2 |
| COMBINATION OF BCL-2 INHIBITOR AND MCL-1 INHIBITOR, USE AND PHARMACEUTICAL COMPOSITIONS THEREOF | 2017 |
|
RU2746705C2 |
| SALTS AND CRYSTALLINE FORMS OF APOTTOSIS-INDUCING AGENT | 2011 |
|
RU2628560C2 |
